Fig. 1 · Structure

Documents & Downloads

Betaxolol hydrochloride

Cat. No. A11733 CAS 63659-19-8
Betaxolol Hydrochloride is a selective beta1 adrenergic receptor blocker used in the treatment of hypertension and glaucoma.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Betaxolol hydrochloride Research Summary

This section summarizes 1 in vitro study and 2 in vivo studies of Betaxolol hydrochloride from 2 published references.

Betaxolol hydrochloride In Vitro Studies

Betaxolol was evaluated in retinal ganglion cell cultures from Wistar rats incubated in AO- medium. Treatment at 100 nM and 1 μM significantly increased viability compared with cultures without betaxolol. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Betaxolol increases retinal ganglion cell viability

Cell-based study · RGC cultures were obtained from the retinas of 6- to 8-day-old Wistar rats; n=8 [1]

In retinal ganglion cell cultures from Wistar rats incubated in AO- medium, Betaxolol at 100 nM and 1 μM significantly increased viability compared with cultures without betaxolol.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
the survival rate of RGC was assessed and normalized to that of the control AO+ conditionRGC viability 69.2±8.6% and 71.0±7.2%[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 nM; 100 nM and 1 μM
Exposure duration
24 h after 72 h incubation in AO+ medium
Method
cells were incubated in AO- medium
Co-treatment
Other interventions in this design: neurobasal medium containing B27 but without anti-oxidants (AO-); BDNF 40 ng/ml; rat CNTF 40 ng/ml; forskolin 10 μM. Compound effect isolated by the comparison: without betaxolol.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Betaxolol

The paper names Betaxolol without stating the salt or form; not verified as the hydrochloride form supplied as A11733. No dose conversion or lot validation.

Methods > Purified rat retinal ganglion cell culture (S8, S15); Methods > Oxidative stress (S17); Methods > Application of β-blockers (S28); Methods > Assay of RGC survival rate (S32, S33); Results > Effect of betaxolol (S54, S55, S56); Figure 4 legend (S82, S84)

the survival rate of RGC was assessed and normalized to that of the control AO+ condition: the survival rate of RGC was assessed and normalized to that of the control AO+ condition; comparator: without betaxolol — Results > Effect of betaxolol (S55, S56); Figure 4 legend (S82)

Betaxolol hydrochloride In Vivo Studies

Betaxolol hydrochloride was administered by i.p. injection to adult male Sprague Dawley rats during cocaine withdrawal. PKA regulatory subunit expression and CREB phosphorylation in amygdalar nuclear extracts significantly decreased compared with cocaine-administered animals that did not receive betaxolol during withdrawal. [2]

Betaxolol decreases PKA regulatory subunit expression during cocaine withdrawal

Animal study · Adult male Sprague Dawley rats; cocaine withdrawal; n=5/treatment group [2]

Adult male Sprague Dawley rats undergoing cocaine withdrawal received Betaxolol hydrochloride at 5 mg/kg by i.p. injection. PKA regulatory subunit expression significantly decreased compared with cocaine-administered animals that received no betaxolol during withdrawal.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
PKA regulatory subunit expression by western blot analysisReported result a significant decrease (p<0.05) in PKA regulatory subunit expression compared to cocaine administered animals that did not receive betaxolol treatment during withdrawal (CS)[2]

Conditions shared by the study groups

Route
i.p. injection
Treatment course
The first dose of betaxolol was administered 24 hours after the final treatment of chronic cocaine or saline. Another dose of betaxolol was administered at 44 hours following cessation of chronic cocaine administration.
Vehicle
0.9 % sodium chloride
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Betaxolol hydrochloride 5 mg/kgcocaine administered animals that did not receive betaxolol treatment during withdrawal (CS)a significant decrease (p<0.05) in PKA regulatory subunit expression compared to cocaine administered animals that did not receive betaxolol treatment during withdrawal (CS)[2]
Betaxolol hydrochloride 5 mg/kg
Model: Adult male Sprague Dawley rats; cocaine withdrawal; n=5/treatment group
Methods and source locations

Compound reported in the paper: Betaxolol hydrochloride; Compound label in the paper: Betaxolol

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Animal Use and Care (S1); Materials and Methods > Drug Treatment (S8, S12, S13, S14, S16); Results > Betaxolol blocks cocaine withdrawal-induced increases in amygdalar PKA regulatory subunit expression (S92, S97)

PKA regulatory subunit expression by western blot analysis: PKA regulatory subunit expression by western blot analysis; comparator: cocaine administered animals that did not receive betaxolol treatment during withdrawal (CS) — Results > Betaxolol blocks cocaine withdrawal-induced increases in amygdalar PKA regulatory subunit expression (S92, S97)

Betaxolol hydrochloride 5 mg/kg · Materials and Methods > Drug Treatment (S12, S13, S14, S16); Results > Betaxolol blocks cocaine withdrawal-induced increases in amygdalar PKA regulatory subunit expression (S97)

Betaxolol decreases CREB phosphorylation during cocaine withdrawal

Animal study · Adult male Sprague Dawley rats; cocaine withdrawal; n=5/treatment group [2]

Adult male Sprague Dawley rats undergoing cocaine withdrawal received Betaxolol hydrochloride at 5 mg/kg by i.p. injection. CREB phosphorylation in amygdalar nuclear extracts significantly decreased compared with cocaine-administered animals that received no betaxolol during withdrawal.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CREB phosphorylation in amygdalar nuclear extractsReported result a significant decrease (p<0.05) in CREB phosphorylation compared to cocaine administered animals that did not receive betaxolol treatment during withdrawal (CS)[2]

Conditions shared by the study groups

Route
i.p. injection
Treatment course
The first dose of betaxolol was administered 24 hours after the final treatment of chronic cocaine or saline. Another dose of betaxolol was administered at 44 hours following cessation of chronic cocaine administration.
Vehicle
0.9 % sodium chloride
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Betaxolol hydrochloride 5 mg/kgcocaine administered animals that did not receive betaxolol treatment during withdrawal (CS)a significant decrease (p<0.05) in CREB phosphorylation compared to cocaine administered animals that did not receive betaxolol treatment during withdrawal (CS)[2]
Betaxolol hydrochloride 5 mg/kg
Model: Adult male Sprague Dawley rats; cocaine withdrawal; n=5/treatment group
Methods and source locations

Compound reported in the paper: Betaxolol hydrochloride; Compound label in the paper: Betaxolol

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Animal Use and Care (S1); Materials and Methods > Drug Treatment (S8, S12, S13, S14, S16); Results > Betaxolol blocks cocaine withdrawal-induced increases in CREB phosphorylation in amygdalar nuclear extracts (S112, S116)

CREB phosphorylation in amygdalar nuclear extracts: CREB phosphorylation in amygdalar nuclear extracts; comparator: cocaine administered animals that did not receive betaxolol treatment during withdrawal (CS) — Results > Betaxolol blocks cocaine withdrawal-induced increases in CREB phosphorylation in amygdalar nuclear extracts (S112, S116)

Betaxolol hydrochloride 5 mg/kg · Materials and Methods > Drug Treatment (S12, S13, S14, S16); Results > Betaxolol blocks cocaine withdrawal-induced increases in CREB phosphorylation in amygdalar nuclear extracts (S116)

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 63659-19-8
Formula C18H29NO3.HCl
Molecular Weight 343.89
Synonyms Betoptic
SMILES
OC(COc1ccc(cc1)CCOCC1CC1)CNC(C)C.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 61 mg/mL (177.38 mM)
Water 61 mg/mL (177.38 mM)
Ethanol 61 mg/mL (177.38 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
Saline

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Betaxolol hydrochloride Research References

  1. [1] Yu ZK, Chen YN, Aihara M, et al. Effects of beta-adrenergic receptor antagonists on oxidative stress in purified rat retinal ganglion cells. Mol Vis (2007). PMID: 17615544 Source material
  2. [2] Rudoy CA, Reyes AR, Van Bockstaele EJ. Evidence for beta1-adrenergic receptor involvement in amygdalar corticotropin-releasing factor gene expression: implications for cocaine withdrawal. Neuropsychopharmacology (2009). PMID: 18596687 DOI: 10.1038/npp.2008.102 Source material

Added to your cart

View Cart Checkout
Loading...